FDA Clearances Put MammoScreen 5 and Heartvue.Proton Into Routine Workflow

New FDA clearances are pushing imaging AI from pilot use into everyday mammography and cardiac MRI workflows, with governance now central to adoption.

Updated

What is this trend?

FDA clearances for MammoScreen 5 and Heartvue.Proton show governed AI moving into routine mammography and cardiac MRI workflows, where version control and validation now matter as much as model performance.

  • MammoScreen 5 is cleared for adjunctive, radiologist-in-the-loop mammogram interpretation.
  • Heartvue.Proton adds cloud viewing, post-processing, and quantitative cardiac MRI analysis.
  • FDA review is shifting from model novelty to workflow fit, update governance, and post-market control.
  • Predetermined Change Control Plans are becoming a key advantage for regulated AI vendors.

What’s the latest?

Therapixel’s MammoScreen 5 and Heartvue.Proton pushed governed AI deeper into routine imaging workflows this week.

How it developed

  1. Reimbursement, real-world evidence, and workflow impact reshape device competition
    • Clinical AI Is Shifting From Model Performance to Regulated Workflow Impact

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Medical Devices & Tools

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.